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Abstract. 
 
The
 
 b
 
2 integrins and intercellular adhesion 
molecule-1 (ICAM-1) are important for monocyte mi-
gration through inflammatory endothelium. Here we 
demonstrate that the integrin 
 
a
 
v
 
b
 
3 is also a key player 
in this process. In an in vitro transendothelial migration 
assay, monocytes lacking 
 
b
 
3 integrins revealed weak 
migratory ability, whereas monocytes expressing 
 
b
 
3 in-
tegrins engaged in stronger migration. This migration 
could be partially blocked by antibodies against the in-
tegrin chains 
 
a
 
L, 
 
b
 
2, 
 
a
 
v, or IAP, a protein functionally 
associated with 
 
a
 
v
 
b
 
3 integrin. Transfection of 
 
b
 
3 inte-
grin chain cDNA into monocytes lacking 
 
b
 
3 integrins 
resulted in expression of the 
 
a
 
v
 
b
 
3 integrin and con-
ferred on these cells an enhanced ability to transmi-
grate through cell monolayers expressing ICAM-1. 
These monocytes also engaged in 
 
a
 
L
 
b
 
2-dependent lo-
comotion on recombinant ICAM-1 which was en-
hanced by 
 
a
 
v
 
b
 
3 integrin occupancy. Antibodies against 
IAP were able to revert this 
 
a
 
v
 
b
 
3 integrin-dependent 
cell locomotion to control levels. Finally, adhesion as-
says revealed that occupancy of 
 
a
 
v
 
b
 
3 integrin could de-
crease monocyte binding to ICAM-1.
In conclusion, we show that 
 
a
 
v
 
b
 
3 integrin modulates
 
 
a
 
L
 
b
 
2 integrin-dependent monocyte adhesion to and mi-
gration on ICAM-1. This could represent a novel mecha-
nism to promote monocyte motility on vascular ICAM-1 
and initiate subsequent transendothelial migration.
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M
 
onocytes
 
 are among the first leukocytes to en-
ter inflamed tissue where they play a vital role in
the healing process. These cells, like other leu-
kocytes, leave the circulation by crossing the vascular en-
dothelium. The dynamic process of transendothelial mi-
gration (TEM)
 
1
 
 in vivo is a multistep mechanism. It
includes initial tethering of leukocytes to the vessel wall,
followed by rolling along the endothelium, tight adhesion
to the endothelial surface, and ultimately movement of the
leukocyte through the intercellular junctions into the un-
derlying tissue (9, 20, 66). The selectin family of adhesion
molecules and their ligands have been implicated in the
initial tethering of leukocytes to the vessel wall through
weak adhesions that permit leukocytes to roll in the direc-
tion of flow (40). Another class of adhesion molecules, the
integrins, of which 
 
b
 
1 and 
 
b
 
2 are key players in TEM (1,
34, 65, 70), mediate arrest, tight adhesion, and spreading of
leukocytes on the endothelium (2). Cellular activation pre-
cedes integrin-mediated adhesion and chemoattractants
are potent activators in vivo (34, 68).
Monocytes express a selection of adhesion molecules in-
cluding selectins, 
 
b
 
1, 
 
b
 
2, and 
 
a
 
v integrins (28, 45). The 
 
b
 
1
integrin 
 
a
 
4
 
b
 
1 present on monocytes promotes arrest and
adhesion to 
 
vascular cell adhesion molecule-1 (
 
VCAM-1) on
the vascular endothelium (1). The 
 
b
 
2 integrins 
 
a
 
L
 
b
 
2 and
 
a
 
M
 
b
 
2 (CD11a/CD18 and CD11b/CD18, respectively) also
present on monocytes (60), bind to the endothelial ligand
ICAM-1 (CD54) (17, 65), and mediate tight adhesion to
the endothelium (70). However, this presents a paradox: if
 
b
 
2 integrins mediate tight adhesion of a leukocyte to
ICAM-1, how does the cell initiate the motility necessary
for subsequent diapedesis? The cell must be able to modu-
late adhesions at the cell surface in order to move forward.
It was recently shown that 
 
a
 
L
 
b
 
2 on lymphocytes can
downregulate 
 
a
 
4
 
b
 
1 integrin activity and enhance cell mo-
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tility on fibronectin (52). We have previously demon-
strated that the 
 
a
 
v
 
b
 
3 integrin can regulate lymphocyte
motility on VCAM-1 by modulating the function of 
 
a
 
4
 
b
 
1
(32).
The 
 
a
 
v
 
b
 
3 integrin can bind to multiple ligands in an
Arg-Gly-Asp–dependent manner (22, 23). The integrin
per se mediates cell locomotion and is involved in cell mi-
gration on components of the extracellular matrix (ECM)
(11, 41). It can also modulate the activity of other inte-
grins, such as phagocytosis mediated by 
 
a
 
5
 
b
 
1 (3) and ad-
hesion through 
 
a
 
M
 
b
 
2 (33, 71). The 
 
a
 
v
 
b
 
3 integrin has been
shown to be physically and functionally associated with in-
tegrin-associated protein (IAP, CD47) (7), a 50-kD mem-
brane protein found on a variety of different cell types
(55), as antibodies against IAP can block some 
 
a
 
v
 
b
 
3 inte-
grin-mediated functions (7, 44). IAP on its own is a recep-
tor for the carboxy-terminal domain of thrombospondin-1
(25), and anti-IAP antibodies can block TEM of leuko-
cytes at a step subsequent to tight adhesion (12). It was re-
cently shown that certain forms of platelet endothelial cell
adhesion molecule (PECAM-1)/CD31 are heterotypic li-
gands for 
 
a
 
v
 
b
 
3 integrin (8, 51). Interestingly, several
groups have shown that antibodies against PECAM-1 are
also able to block TEM (49, 72). Therefore, there is some
evidence to suggest that the
 
 a
 
v
 
b
 
3 integrin might be in-
volved in TEM.
We looked specifically at the role of 
 
a
 
v
 
b
 
3 integrin in
monocyte migration. A 
 
b
 
3 integrin-deficient monocytic
cell line displayed poor migratory ability compared with a
 
b
 
3 integrin-positive monocytic cell line in TEM assays.
Antibodies against 
 
a
 
v or IAP inhibited transmigration of
 
b
 
3-positive monocytes. Moreover, transfection of the 
 
b
 
3
chain into 
 
b
 
3-deficient cells with subsequent expression of
 
b
 
3 integrins conferred on these cells an enhanced ability to
transmigrate. In the process of elucidating the mechanism
of this enhanced transmigration, we found that 
 
b
 
3 inte-
grin-positive monocytic cells preferentially transmigrated
through ICAM-1–expressing cell monolayers. Subsequent
studies of monocyte locomotion on recombinant ICAM-1
and adhesion assays revealed a cross talk mechanism be-
tween 
 
a
 
v
 
b
 
3 integrin and 
 
a
 
L
 
b
 
2 integrin on monocytes
which affects monocyte binding to and migration on
ICAM-1.
Our results point to a role for the 
 
a
 
v
 
b
 
3 integrin in 
 
b
 
2 in-
tegrin-dependent migration of monocytes on ICAM-1,
which could be a mechanism that enables monocytes to
overcome tight adhesion to endothelial ICAM-1 under in-
flammatory conditions and engage in subsequent TEM.
 
Materials and Methods
 
Cell Lines
 
J774.2 and WEHI-3 murine monocytic cell lines were obtained from
American Type Culture Collection (Rockville, MD). The mouse endothe-
lioma cell line e.end2 was from W. Risau (Max-Planck, Bad Neuheim,
Germany). Untransfected L cells and L cells transfected with full-length
CD31 were obtained from S. Albelda (The Wistar Institute, Philadelphia,
PA) and have previously been described (14). The L cells transfected with
ICAM-1 were obtained from C. Figdor (University Hospital, Nijmengen,
The Netherlands). The THP-1 human monocytic cell line was obtained
from the lab of A. Lanzavecchia (The Basel Institute for Immunology,
Basel, Switzerland).
 
Medium and Reagents
 
J774.2, e.end2, untransfected L cells, and L cells transfected with CD31
were grown in DME media (GIBCO BRL, Paisley, Scotland) supple-
mented with 10% FCS (GIBCO BRL, Auckland, New Zealand), nones-
sential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml
streptomycin (all from GIBCO BRL, Auckland) and 5 
 
3 
 
10
 
2
 
5
 
 M 2-mercapto-
ethanol (Fluka, Buchs, Switzerland). WEHI-3 cells were grown in Iscove’s
modified Dulbecco’s (IMDM) media (GIBCO BRL, Paisley) supplemented
as above. Murine 
 
b
 
3-transfected WEHI-3 cells were cultured in IMDM
with 0.5 g/liter geneticin, (G418 sulfate from Calbiochem-Novabiochem
Corp., La Jolla, CA). L cells transfected with ICAM-1 were cultured in
IMDM with 1 g/liter of G418. The human monocytic cell line THP-1 was
cultured in RPMI (GIBCO BRL, Paisley) with 10% FCS. Human unbilical
vein endothelial cells (HUVEC) cells were obtained from U. Vischer (Centre
Médical Universitaire, Geneva, Switzerland) at first or second passage.
The mouse soluble recombinant adhesion molecules ICAM-1, PE-
CAM-1, and VCAM-1 have been previously described (51). Soluble re-
combinant human ICAM-1 was obtained from J.E. Meritt (Roche Prod-
ucts Ltd., Herts, UK). The mouse and human chemokine MCP-1 used in
the transmigration assays were from R&D Systems, Inc. (Abingdon, UK).
Mouse and human TNF-
 
a
 
 and mouse laminin were all from GIBCO BRL
(Paisley). Human plasma fibronectin and human plasma vitronectin were
from Collaborative Research (Bedford, MA). BSA was from Sigma
Chemical Co. (Buchs, Switzerland).
 
Other Reagents and Antibodies
 
For FACS
 
®
 
 analysis the following antibodies were used: anti-
 
b
 
3, anti-
 
a
 
M,
anti 
 
a
 
4, anti-CD31 (all from PharMingen, San Diego, CA), anti-MHC
class II, anti-
 
a
 
v, anti-IAP, anti-
 
a
 
6 (EA-1) (57) and anti-
 
a
 
L (see below).
For TEM and migration assays on ICAM-1, only affinity-purified preser-
vative-free antibodies were used. The anti-mouse antibodies were anti-
 
a
 
v
integrin (RMV-7 from H. Yagita [Juntendo University, Tokyo, Japan]),
anti-
 
a
 
L (FD441.8) (61), anti-
 
a
 
4 (PS/2) (48), anti-IAP (MIAP 301) (43),
anti MHC class II (M5/114) ATCC TIB 120, and anti-
 
a6 (GoH3) (53).
The anti-human antibodies directed against the integrins b1 (JB1a), b2
(P489-A11), avb3 (LM609), avb5 (P1F6), and av (CLB-706), and anti-
MHC class I were all from Chemicon (Temecula, CA). Anti-human IAP
(B6H12) has previously been described (7, 26). The anti-aL subunit func-
tion blocking antibody (mAb 38) was from the lab of N. Hogg (Imperial
Cancer Research Fund, London, UK) (52).. For cross-linking experiments,
the following secondary affinity-purified preservative-free polyclonal anti-
bodies were used: Fc fragment-specific goat anti–rat IgG and Fc fragment-
specific goat anti–mouse IgG (Chemicon). Rabbit antibodies against hu-
man fibronectin (Sigma Chemical Co., St. Louis, MO) or against human
fibrinogen (Dako A/S, Copenhagen, Denmark), both cross-reactive with
the mouse proteins, were used in the immunofluorescent studies. The sec-
ondary reagent was a FITC-labeled goat anti–rabbit antibody (Southern
Biotechnologies, Birmingham, AL).
Isolation of Human Peripheral Blood Monocytes
Human blood from healthy donors was collected with heparin (Liquemin;
Roche). Peripheral blood mononuclear cells were separated from whole
blood by density gradient centrifugation using Ficoll-hypaque (Pharmacia
Biotech., Inc., Dübendorf, Switzerland). Monocytes were then separated
from the lymphocytes using a Percoll gradient (Pharmacia Biotech., Inc.).
The isolated monocytes were used within 48 h for TEM assays or FACS®
analysis, and cultured in RPMI medium with 10% FCS (Boehringer Mann-
heim, Mannheim, Germany).
Stable Transfection of the b3 Integrin Chain into 
WEHI-3 Cells
A 2.6-kb cDNA fragment containing the entire mouse b3 integrin coding
region was excised from the pBluescript II KS2 vector with BamHI and
XhoI and then inserted into the pcDNA3 vector (Invitrogen, Leek, The
Netherlands). WEHI-3 cells were transfected using the lipofectamine
method. Briefly, 12 mg of DNA in a 50-ml volume was mixed with 30 ml of
lipofectamine (GIBCO BRL, Basel, Switzerland) in a total volume of 100 ml
with distilled water. After a 15-min incubation at room temperature, this
was added dropwise to 5 3 106 WEHI-3 cells in 3 ml Opti-MEM (GIBCO
BRL, Paisley). After 24 h at 378C without serum, 3 ml of medium contain-
ing 20% FCS was added and cells were left for another 24 h at 378C. Cells
were then harvested and cultured in medium with 500 mg/ml geneticinWeerasinghe et al. avb3 Integrin and Monocyte Migration 597
and seeded at limiting dilution into 96-well plates. Colonies were picked
14 d later. Cell clones were expanded individually and clones expressing
the b3 integrin chain were selected by FACS® analysis. These were then
expanded further.
Flow Cytometry
Suspension and trypsinized adherent cells were collected and resuspended
in Dulbecco’s PBS with 1% BSA. Cells (105 per sample) were washed
twice in this medium and then resuspended in DPBS/BSA with saturating
amounts of mAbs. After a 30-min incubation at 48C, cells were washed
twice in DPBS/BSA and then resuspended in staining solution containing
FITC-labeled goat anti–rat IgG (Jackson ImmunoResearch, Milan, Italy
and Analytica, La Roche, Switzerland) for rat monoclonals, FITC-labeled
goat anti–hamster IgG for hamster monoclonals, or FITC-labeled goat
anti–rabbit IgG for antibodies raised in rabbit (Southern Biotechnologies,
Birmingham, Alabama). After another 30-min incubation at 48C, cells
were washed twice, resuspended in the staining solution containing 0.1%
propidium iodide, and then analyzed by flow cytometry (FACScan®; Bec-
ton Dickinson Co., Mountain View, CA). Control cell suspensions were
incubated with secondary antibody alone.
Transendothelial Migration Assay
Transwell culture inserts of 24-well tissue culture plates (6.5-mm-diam
polycarbonate membranes with 5 mm diameter pores [Costar Corp., Cam-
bridge, MA]) were coated with 50 mg/ml laminin in Earle’s balanced salt
solution for 30 min. Excess laminin was removed from the inserts and
e.end2 cells at 106/ml were seeded on the inserts in 100 ml of medium.
Cells were allowed to grow to confluence on filters for 48 h. Cell conflu-
ence was checked by staining some filters with May-Grunwald-Wright-
Giemsa solution (Fluka) followed by microscopic control. The cultures
were then washed once in DME with 5% FCS and then preincubated in
medium with or without 20 ng/ml of TNF-a for 5 h at 378C, after which the
cultures were washed twice with medium.
Cells of the J774.2 or WEHI-3 line were washed once in medium and
then adjusted to 106 cells/ml. 100 ml of cell suspension were added per in-
sert. Thereafter, 300 ml of medium were placed into the lower chambers of
the Transwells with 125 ng/ml of monocyte chemoattractant protein-1
(MCP-1). The inserts were carefully placed into the lower chambers to
avoid air bubbles forming at the interface between the underside of the in-
sert and the medium. Migration was allowed to proceed for 4 h at 378C.
The assay was stopped by removing the medium from the upper well and
rinsing the upper surface of the insert twice with 0.2% EDTA in PBS. The
number of cells which had migrated into the lower chamber was determined
by light microscopy at a magnification of 10. Alternatively for the human cell
experiments, HUVECs were cultured for 48 h on filters precoated with 50
mg/ml fibronectin. The rest of the assay was as described before. However,
freshly isolated human monocytes were allowed to transmigrate for 2 h.
For antibody-blocking studies, 300 ml of monocytic cells at 106 cells/ml
were spun down and re-suspended in 100 ml of medium in an Eppendorf
tube (Hamburg, Germany). The antibodies were added to a final concen-
tration of 50 mg/ml. The tubes were then incubated on a shaker for 40 min
at 48C. Before the assay, cells were spun down, washed once in medium,
and then resuspended in 300 ml of fresh medium. This was then added to
three wells per condition. For each experiment, the number of cells which
had transmigrated was expressed as the mean value of cells counted in
three wells.
Transmigration through L Cells
Basically, the same method as for endothelial cells was used. Untrans-
fected L cells, L cells expressing PECAM-1, or L cells expressing ICAM-1
were seeded at a concentration of 105 cells per well on laminin-precoated
inserts and then allowed to grow to confluence for 48 h. Cultures were
washed once in medium and monocytic cells were added in a 100-ml vol-
ume to the upper well. Chemokines were used at the same concentration
as in the TEM assay. Cell confluence was checked as before. For this ex-
periment, the mean value of transmigrated cells counted in three wells
was expressed as a percentage of the total number of cells added per well.
Cell Migration Assay
Single wells of a 96-well plate (Serocluster; Costar Corp.) were coated
with 2.4 mM of recombinant soluble adhesion molecules. This concentra-
tion has been shown to be the saturating concentration for a single well of
a 96-well plate (32). A typical saturating coating consisted of either 100%
mouse or human ICAM-1. In the case of mixes, the saturating coating
consisted of 99% ICAM-1 and 1% CD31, obtained by mixing 2.376 mM
of ICAM-1 and 0.024 mM of CD31. The total protein concentration re-
mained at 2.4 mM. For the control experiments z1% vitronectin or z1%
laminin was used. Wells were coated for 1 h with protein and then blocked
for 1 h with 20% BSA, all at room temperature, after which wells were
washed three times with serum-free medium. 105 cells in the exponential
growth phase were washed once with 500 ml of serum-free medium, resus-
pended in 100 ml, added to a coated well, and then allowed to adhere at
378C for 5 min. Nonadherent cells were washed away by gently adding 100
ml of medium to the well and exchanging this volume twice. The plate was
then placed under an Axiovert 100 television microscope (Carl Zeiss AG,
Jena, Germany) equipped with an incubator chamber. The temperature of
the air and the microscope plate was maintained at 378C by a TRZ 3700
unit and the CO2 level (10 or 5%) was controlled by a CTI controller 3700
(all from Carl Zeiss AG). Continuous recording of cell migration was per-
formed using a 203 objective with video time-lapse equipment.
During incubation, antibodies were added manually in a volume of 10 ml
using a Gilson pipette and a curved multiprecision tip (Sorenson Bioscience,
Inc., Salt Lake City, Utah). Before the addition of antibody, cells were allowed
to migrate on the substrate for 40 min in order to record locomotion in the
absence of antibody. After antibody had been added, cell locomotion was
recorded for another 40 min. To block molecules on the cell surface, anti-aL
or anti-IAP antibodies were added at a final concentration of 50 mg/ml. To
cross-link molecules, anti-av, anti-b2, anti-a6 or anti-major histocompati-
bility complex (MHC) antibodies were used at a final concentration of 10
mg/ml, together with 10 mg/ml of secondary anti-Fc–specific antibody.
Data Analysis
After completion of the assay, the video was played 60 times faster on a
Sony color video television. The displacement of individual cells was
traced on transparent write-on films. A minimum of 10 tracks were fol-
lowed for 30 min in each experiment. Migration distance was measured in
centimeters for each track using a curvimeter. Results are expressed in
mm/h by using the conversion factor 8 cm 5 100 mm.
Immunofluorescent Studies
L cells expressing ICAM-1 were trypsinized and cultured on eight cham-
ber glass slides (Nunc, Inc., Naperville, IL) for 24 h. Cells were fixed in
ice-cold acetone for 7 min and then allowed to air dry. Wells were blocked
with 10% FCS in PBS for 30 min after which primary antibody was added
at a 1:50 dilution in PBS/BSA. This was left at room temperature for 30
min, after which the secondary FITC-labeled antibody was added and left
for another 30 min. Each step was followed by a washing step in PBS and
distilled water.
Cell Bead Attachment Assay
Ligand-coated beads were prepared as described previously (52). Briefly,
200 ml (108) of 3.2-mm polystyrene beads (Sigma Chemical Co.) were
washed twice in distilled water followed by two further washes and resus-
pension in 0.1 M bicarbonate buffer, pH 9. ICAM-1 or fibronectin (con-
trol) was added to the beads at a final concentration of 10 mg/ml. To pre-
pare BSA-coated control beads, they were incubated with 2% BSA. The
beads were rotated for 1 h, washed once in PBS and blocked with 2%
BSA for 2 h, all at room temperature. Finally, the beads were washed
twice in 20 mM Hepes, 140 mM NaCl, and 2 mg/ml glucose, pH 7.4 (assay
buffer).
Multiwell Lab-Tek chamber slides (Nunc, Inc.) were coated overnight
at 48C with the following molecules: recombinant ICAM-1; vitronectin;
anti-avb3, anti-avb5, anti-a6, anti-b2, and anti-MHC class I antibodies; all
at 50 mg/ml or BSA. The next day, the wells were washed twice with PBS
and nonspecific binding sites were blocked with 2% BSA at room temper-
ature for 2 h. THP-1 monocytic cells (150 ml of 2 3 106/ml) in assay buffer
were added to the wells and allowed to settle on ice for 15 min. Freshly
prepared ligand-coated beads were then added to the wells at a 100:1
bead/cell ratio in 50 ml of assay buffer. After 30 min at 378C, unbound
beads and cells were removed by washing the wells four times in pre-
warmed assay buffer. Bound cells were fixed with 1% formaldehyde in
PBS for 20 min and the cells were then stained with haematoxylin for 10
min. 100 cells were counted under the microscope (403 oil immersion ob-The Journal of Cell Biology, Volume 142, 1998 598
jective; Carl Zeiss AG, Jena, Germany) and the number of beads which
had bound to these cells was determined (attachment index). For anti-
body-blocking studies, anti-aL (mAb38), anti-b1, or anti-a6 was added to
the cells at a final concentration of 50 mg/ml and left for 15 min at 48C be-
fore the addition of beads.
Results
The avb3 Integrin Is Involved in Monocyte 
Transendothelial Migraton
To study molecules involved in TEM we set up an in vitro
assay. A murine endothelial cell line was grown to conflu-
ence on laminin-precoated polycarbonate filters with de-
fined 5-mm-diam pores. Several murine monocytic cell
lines were screened for their ability to transmigrate. In
vivo, monocytes preferentially home to acute inflamma-
tory tissue. Inflammation is accompanied by increased ex-
pression of both ICAM-1 and VCAM-1 on the endothe-
lium, which are essential molecules for leukocyte TEM
(47). We therefore treated the endothelial monolayer with
the inflammatory cytokine TNF-a, which led to increased
expression levels of ICAM-1 and VCAM-1 as determined
by FACS® analysis (data not shown). As a soluble gradi-
ent of endogenous chemokine promotes the TEM of
monocytes in vitro (54), we included the chemokine MCP-1
in our assay (69). An optimal concentration of 125 ng/ml
was chosen because MCP-1 has been shown to be maxi-
mally chemotactic at around this concentration (56). As
expected, transmigration of monocytes was more efficient
through the TNF-a–activated endothelial monolayer. The
J774.2 monocytic cell line was able to selectively migrate
through the endothelial monolayer, but not through plain
filters or filters coated with ECM molecules alone (Fig. 1
and data not shown). In comparison, the WEHI-3 mono-
cytic cell line transmigrated threefold less efficiently
through the endothelial monolayer. We performed FACS®
analysis on the J774.2 and WEHI-3 cells to quantitate the
expression levels of different adhesion molecules known
to play a role in leukocyte migration. Although both
J774.2 and WEHI-3 cells expressed aL, aM, a4, a6 and av
integrin chains, and IAP, b3 integrin chain expression was
markedly low on WEHI-3 cells (Fig. 2). There was no dif-
ferential expression of PECAM-1 on the two murine cell
lines (data not shown).
b3 integrins have not previously been described to play
a role in monocyte TEM. However, previous experiments
have shown that IAP plays a role in the TEM of some leu-
kocyte subsets, whereas others have shown that IAP is
necessary for some avb3-mediated functions (7). The ad-
hesion molecule PECAM-1, found on circulating leuko-
cytes and endothelial cells, is another molecule involved in
TEM (49, 72). We previously demonstrated that some
forms of PECAM-1 can interact with the avb3 integrin.
We investigated the effect of antibodies against the av
integrin chain in the in vitro assay. These antibodies were
able to block TEM of J774.2 cells by 50% through TNF-
a–activated endothelium as shown in Fig. 3 a. Antibodies
against IAP, aL, and a4 integrins but not against a6 or
MHC class II also blocked TEM under inflammatory con-
ditions. Although these experiments reinstated the impor-
tance of IAP, aL, and a4 for monocyte TEM, they also in-
dicated that av integrins were involved in the process. In a
subsequent TEM assay using primary HUVEC cell cul-
tures as the endothelial monolayer, we tested the ability of
human peripheral blood monocytes to transmigrate under
normal and inflammatory conditions. Antibodies against
b2 and av integrins were able to inhibit TEM across non-
activated endothelium by 50%, whereas anti-b1 had no ef-
fect (Fig. 3 b). This was consistent with the fact that nonac-
tivated endothelium does not express the a4b1 ligand
VCAM-1. As a result of TNF-a treatment, HUVECs ex-
press VCAM-1, and ICAM-1 levels are increased (data
not shown). This resulted in a twofold enhancement of
TEM which could be inhibited by anti-b1, anti-b2, and
anti-av antibodies (Fig. 3 b). Control anti-MHC class I an-
tibodies had no effect on TEM under either condition.
Freshly isolated human monocytes express the avb3 inte-
grin albeit at lower levels than b2 integrins (Fig. 3 c).
Enhanced TEM of WEHI-3 Cells Transfected with 
Full-length b3 cDNA
To clarify the importance of the avb3 integrin in TEM, b3-
deficient WEHI-3 cells were transfected with full-length
mouse b3 integrin cDNA. WEHI-3 clone 1D10 expressed
b3 integrin chains and also showed increased expression
levels of av as compared with clone 3E9 which did not ex-
press b3 integrin chains (Fig. 4). A further WEHI-3 clone
(1C10) expressing similar levels of the b3 integrin chain to
clone 1D10 (data not shown), was also selected for subse-
quent TEM assays. The WEHI-3 b31 clones 1D10 and
1C10 exhibited an enhanced ability to transmigrate under
inflammatory conditions as compared with the b32 clone
3E9, and also surpassed J774.2 cells (Fig. 5 a). Further-
more, antibody-blocking studies on clone 1D10 and clone
3E9 cells showed that anti-aL and anti-av integrin anti-
bodies could inhibit TEM of clone 1D10 cells (Fig. 5 b).
An antibody against a6 integrin or MHC class II, had no
effect on TEM.
To compare the transmigratory capacity of the WEHI-3
Figure 1. In vitro migration
of monocytic cells across an
endothelial cell layer. Murine
monocytic J774.2 and WEHI-3
cells were used in the TEM
assay as described in Materials
and Methods. J774.2 cells do
not transmigrate through ei-
ther plain filters or ECM-
coated filters (data not
shown). Transmigration was
allowed to proceed across a
preestablished layer of unac-
tivated (dotted bars) or TNF-
a–activated (solid bars) e.end2 endothelioma cells for 4 h at 378C.
Cells that had passed through the endothelial cell layer into the
lower chamber were counted. J774.2 cells transmigrated more ef-
ficiently than WEHI-3 cells through nonactivated or activated en-
dothelium. The results are expressed as the arithmetic mean of
the number of cells 6 SE from three wells per condition. A repre-
sentative experiment out of three is shown.Weerasinghe et al. avb3 Integrin and Monocyte Migration 599
parental cell line with clone 1D10, we compared their abil-
ity to transmigrate through an inflammatory endothelium
versus plain laminin-coated filters. WEHI-3 and clone
1D10 cells transmigrated at comparable levels through
laminin-coated filters. However, only clone 1D10 cells
transmigrated significantly through inflammatory endo-
thelium (Fig. 5 c). These experiments demonstrated the
importance of the avb3 integrin in monocyte TEM.
Figure 2. Flow cytometry to
determine expression levels of
MHC class II, IAP, and the in-
tegrin chains a6, b3, av, a L,
aM, and a4 on the J774.2 and
WEHI-3 murine monocytic
cells. J774.2 cells expressed all
the molecules tested, whereas
b3 integrin chain expression
was markedly low on WEHI-3
cells.
Figure 3. Inhibition of mu-
rine and human monocyte
TEM by antibodies against
the  av integrin chain. Details
of the TEM assay are de-
scribed in Materials and
Methods. (a) Effect of anti-
bodies on TEM of murine
J774.2 monocytic cells across
a TNF-a–activated e.end2
endothelial monolayer. TEM
in the absence of any anti-
body (cont) or in the pres-
ence of anti-MHC, anti-a6,
anti-av, anti-IAP, anti-aL or
anti-a4. (b) Effect of differ-
ent antibodies on TEM of
freshly isolated human pe-
ripheral blood monocytes
across a layer of nonactivated
(dotted bars) or TNF-a–acti-
vated (solid bars) HUVEC
cells. TEM was allowed to
proceed at 378C for 2 h. Anti-
bodies against b2 or av
blocked TEM of cells under nonactivated conditions, whereas under activated conditions TEM increased and antibodies against b1, b2,
or av were able to block this. Results are the arithmetic means (6 SE) of the number of cells from three wells per condition. A represen-
tative experiment out of three is shown. (c) FACS® analysis of freshly isolated human peripheral blood monocytes for expression of
avb3 and b2 integrins. Human monocytes expressed avb3 albeit at lower levels than b2 integrins.The Journal of Cell Biology, Volume 142, 1998 600
Transmigration Is Increased through L Cells
Expressing ICAM-1
Expression of the avb3 integrin is known to be required
for cell migration on ECM substrates (11, 22, 58, 59). To
examine how the avb3 integrin increases cell migration in
our studies, we used a modified transmigration assay. Fi-
broblast type L cells, which express the avb3 ligand fi-
bronectin (data not shown) were used in lieu of the endo-
thelial monolayers and grown to confluence on nucleopore
filters. Neither J774.2 nor WEHI-3 b31 clone 1D10 cells
were able to transmigrate efficiently through these L cells
(Fig. 6). We then used L cells expressing PECAM-1.
Again, we could not detect significant transmigration of
monocytic cells. In contrast, when L cells expressing
ICAM-1 were used in the assay, we found that both J774.2
and WEHI-3 b31 cells were able to transmigrate very effi-
ciently, though ICAM-1 is not a known ligand for avb3
(2% of added J774.2 cells and 6% of added WEHI-3 b31
cells transmigrated). L cells transfected with ICAM-1 also
expressed fibronectin but not fibrinogen (Fig. 7), the latter
can act as a bridging molecule between ICAM-1 and the
aMb2 integrin (38). Therefore, it was conceivable that the
binding of fibronectin to avb3 potentiated the transmigra-
tion of monocytes across ICAM-1. However, this implied
the existence of a cross talk mechanism between avb3 in-
tegrin and b2 integrins on the monocyte.
Monocyte Migration on Recombinant Molecules
To investigate a potential cross talk mechanism, we ana-
lyzed the migratory behavior of WEHI-3 b31 cells on re-
combinant ICAM-1. Recombinant ICAM-1 was coated on
plastic at a concentration of 2.4 mM, which has been deter-
mined to be the saturating protein concentration for these
assays (32). Furthermore, this concentration is consistent
with the expression levels of ICAM-1 on cytokine activated
e.end2 monolayers as determined by ELISA (data not
shown). Monocytes are able to migrate on recombinant
ICAM-1 and this migration could be decreased by antibod-
ies against the aL integrin chain but not with antibodies
against MHC class II molecules (Fig. 8 a). In the first 10
min after the addition of anti-aL, the cells begin to lose
their adherent morphology and start to round up. They re-
duce their velocity of migration and reach a stationary
phase 50 min after the addition of antibody. Cell migration
was recorded during the first 40 min of the experiment.
When a low concentration of PECAM-1 or vitronectin,
also a ligand for avb3, was coated together with ICAM-1,
Figure 4. FACS® analysis of the expression levels of the av and
b3 integrin chains on WEHI-3 cells that had been transfected with
full-length mouse b3 cDNA. (a) Clone 1D10 expressed the b3 in-
tegrin chain. (b) Clone 3E9 did not express the b3 integrin chain.
Figure 5. Migration of J774.2 or b3 chain transfected WEHI-3 monocytic cells across TNF-a–activated e.end2 endothelial monolayers.
(a) Comparison of TEM of J774.2 and WEHI-3 clones. Clones 1D10 and 1C10 express b3 integrins. Clone 3E9 is a b3 nonexpressing
clone. (b) Effect of antibodies against MHC class II, av, a6, or aL integrins on TEM of WEHI-3 b31 clone 1D10 cells (solid bars) and
WEHI-3 b32 clone 3E9 cells (hatched bars). TEM of clone 1D10 was inhibited by anti-av or anti-aL integrin antibodies. (c) Comparison
of the transmigratory capacity of the WEHI-3 parental cell line with clone 1D10 through laminin-coated filters or activated endothe-
lium. Both the WEHI-3 parental cell line and clone 1D10 transmigrated at comparable levels through laminin-coated filters (hatched
bars). However, only clone 1D10 cells were able to transmigrate through activated endothelium (solid bars). Details of the assays are
described in Materials and Methods. Results are the arithmetic mean (6 SE) of cells from three wells per condition. A representative
experiment out of three is shown.Weerasinghe et al. avb3 Integrin and Monocyte Migration 601
the speed of cell locomotion increased (Fig. 8 b). In contrast,
coating the same concentration of laminin together with
ICAM-1 had no effect (Fig. 8 b). Subsequently, cell locomo-
tion on a mixture of ICAM-1 and PECAM-1 could be inhib-
ited by antibodies against IAP, the protein associated with
some functions of the avb3 integrin. In contrast, anti-IAP did
not decrease the speed of monocyte locomotion on ICAM-1
alone (Fig. 8 c). In these experiments, whereas ICAM-1 coat-
ing was at 99% saturation, coating of PECAM-1, vitronectin,
or laminin was at 1% saturation. The 1% saturation of differ-
ent proteins alone does not support cell adhesion or migra-
tion on surfaces (data not shown).
In addition, we observed a 1.4-fold increase in cell mi-
gration on ICAM-1 alone when av was cross-linked on the
cell surface by antibodies (Fig. 9 a). Cross-linking antibod-
ies against MHC class II had no effect. To determine
whether the effect of av cross-linking on monocytes was
specific for b2 integrins, or if it could also influence the ac-
tivity of other integrins important in TEM such as a4b1,
we looked at monocyte migration on recombinant VCAM-1.
As can be seen in Fig. 9 b, cross-linking av on monocytes
migrating on VCAM-1 failed to increase their speed of lo-
comotion and cross-linking the a6 integrin chain as a con-
trol also had no effect. Surface molecule cross-linking was
done in the presence of a low concentration of primary
antibody (10 mg/ml) plus a secondary anti-Fc antibody
(10 mg/ml), to ensure capping of the integrin/MHC on the
cells for lateral migration. This is contrary to the effect of an-
tibodies used in the TEM-blocking studies. There, 50 mg/ml
of primary antibody alone was used, to ensure blocking
and not capping of cell surface molecules.
Finally, we compared locomotion of cells of the WEHI-3
b31 clone 1D10 with cells of the WEHI-3 b32 clone 3E9,
on recombinant ICAM-1. Clone 1D10 and clone 3E9 cells
migrated at comparable levels on ICAM-1 alone. How-
ever, after av cross-linking, locomotion was enhanced only
with cells of clone 1D10 (Fig. 9 c). Clone 3E9 cells did not
respond to cross-linking of the av integrin chain. 
These experiments were repeated with the human
monocytic cell line THP-1, which expresses aLb2 and
avb3 integrins (tested by FACS®, data not shown). From
Fig. 10 a, it is clear that locomotion of THP-1 monocytic
cells on recombinant ICAM-1 was increased 2.5-fold upon
cross-linking of the av integrin chain, but cross-linking the
a6 or b2 integrin chains had no effect. (The anti-mouse a6
antibody recognizes a6 integrins on THP-1 cells as de-
tected by FACS®; data not shown). In a further experi-
ment, the effect of blocking aLb2 on monocytic cells after
enhancing their migration on ICAM-1 by cross-linking av,
was assessed by adding an anti-aL antibody. As can be
seen in Fig. 10 b, cell motility on ICAM-1 returned to con-
trol levels after addition of anti-aL, an indication that
modulation of cell migration on ICAM-1 by av is depen-
dent on the function of the aLb2 integrin. THP-1 cell mi-
gration was also enhanced twofold on a mixture of ICAM-
1/vitronectin which could be decreased by antibodies
against IAP. Again, anti-IAP had no effect on monocyte
migration on ICAM-1 alone (Fig. 10 c). Finally, as a con-
trol for integrin cross talk on monocytic cells, we looked at
the effect of cross-linking av on THP-1 cells migrating on
laminin to determine whether av integrins could influence
a6 integrins. As can be seen from Fig. 10 d, background
migration on laminin was low. However, there was no in-
crease in cell locomotion of monocytes on laminin after
cross-linking the av integrin chain.
Effect of avb3 Integrin Occupancy on ICAM-1 Binding
To determine the effect of avb3 occupancy on the func-
tion of b2 integrins, we investigated the ability of THP-1
monocytic cells to bind beads coated with ICAM-1 upon
adherence to immobilized BSA, anti-MHC class I, ICAM-1,
vitronectin, or antibodies against the integrins avb5 (THP-1
cells express avb5; data not shown), avb3, a6, and b2. The
data summarized in Fig. 11 a show that monocytes adher-
ent on anti-MHC class I, anti-avb5, anti-a6, and anti-b2
Figure 6. Transmigration of J774.2 and b3 chain transfected
WEHI-3 cells across layers of untransfected L cells, L cells trans-
fected with CD31, or L cells transfected with ICAM-1. Transmi-
gration required the expression of the b3 integrin chain on mono-
cytes (J774.2, dotted bars and WEHI-3 b31, solid bars) as well as
the expression of ICAM-1 on L cells. Under no circumstance did
transmigration of WEHI-3 b32 cells occur efficiently (hatched
bars). Details of the assay are described in Materials and Meth-
ods. Cell migration is expressed as a percentage of the total num-
ber of cells added per well. The data represent the arithmetic
mean (6 SE) of cells from three wells per condition. A represen-
tative experiment out of three is shown.
Figure 7. Immunofluorescent
studies on L cells transfected
with ICAM-1 for expression
of fibronectin and fibrinogen.
L cells were cultured for 24 h
and tested for fibronectin or
fibrinogen expression as de-
scribed in Materials and
Methods. L cells transfected
with ICAM-1 expressed fi-
bronectin (A) but not fibrino-
gen (B).The Journal of Cell Biology, Volume 142, 1998 602
antibodies or ICAM-1, bound ICAM-1–coated beads at
comparable levels. However, if the cells were allowed to
interact with an anti-avb3 antibody or vitronectin, signifi-
cantly fewer ICAM-1–coated beads were bound. The
epitope for the anti-avb3 antibody used here (LM609), is
near the Arg-Gly-Asp binding site of the integrin (4).
Therefore, binding of the antibody to the integrin could
mimic integrin occupancy. As a control, the ability of
THP-1 cells to bind fibronectin-coated beads under similar
conditions was assessed. Cells immobilized on anti-avb3
or vitronectin bound similar numbers of fibronectin coated
beads as compared with cells immobilized on other sub-
strates (Fig. 11 b). Hardly any monocytes adhered to BSA
(data not shown) and there was only negligible binding of
BSA-coated beads to monocytes immobilized on the dif-
ferent substrates (Fig. 11 b).
Last but not least, we tested whether anti-aL integrin
antibodies could block the binding of ICAM-1–coated
beads to THP-1 cells adherent on ICAM-1. As can be seen
from Fig. 12 b, addition of 50 mg/ml of this antibody dra-
matically reduced binding of ICAM-1–coated beads to the
cells. On the other hand, addition of a control antibody
against a6 integrin had no effect (Fig. 12 a). Moreover, an
anti-b1 integrin antibody reduced binding of fibronectin
coated beads to THP-1 cells immobilized on ICAM-1 (Fig.
12 d), whereas the anti-a6 antibody again had no effect
(Fig. 12 c).
Discussion
Although much is known about the rolling and tight adhe-
sion steps before TEM, little is known about the events
that lead to transition from tight adhesion to migration of
a leukocyte on the apical surface of the endothelium and
subsequent diapedesis between the endothelial cells to the
basal side of the blood vessel wall. The b1 and b2 integrins
mediate tight adhesion of the leukocyte to inflammatory
vascular endothelium. However, induction of TEM re-
quires a dynamic regulation of adhesion of these integrins
to their respective ligands. Our results indicate that occu-
pancy of avb3 integrin on monocytes can modulate b2 in-
tegrin-dependent adhesion to and migration on ICAM-1.
This could be a mechanism which enables monocytes to
overcome tight adhesion to endothelial ICAM-1 under in-
flammatory conditions and engage in subsequent TEM.
J774.2 monocytic cells expressing the avb3 integrin trans-
migrated through TNF-a–activated endothelium, whereas
WEHI-3 cells deficient in this integrin were hampered in
the process. TEM of J774.2 cells could be partially blocked
under inflammatory conditions by antibodies against IAP,
a4b1, aLb2 and av integrins. TEM assays carried out with
primary human monocytes reinstated that b2 and av inte-
grins are important in this process. Transfection of b3 inte-
grin chain cDNA into WEHI-3 cells resulted in expression
of the avb3 integrin on the cell surface. These cells were
then able to engage in enhanced TEM through TNF-a–acti-
vated endothelium which could be inhibited by antibodies
against  aL or av. Although these experiments demon-
strate the importance of the avb3 integrin in monocyte
TEM, they do not reveal how the integrin is involved in
the process. The integrin avb3 can mediate cell spreading
and migration on immobilized vitronectin (41, 42), and is a
molecule involved in tumor metastasis (63). The integrin is
also upregulated on proliferating endothelial cells (24),
and initiates a Ca12-dependent signaling pathway that
leads to endothelial cell migration and the process of an-
giogenesis (6, 42). To study how the avb3 integrin is in-
volved in TEM, we modified the transmigration assay by
Figure 8. WEHI-3 b31 monocyte migration on recombinant
ICAM-1. Recombinant ICAM-1 was coated at 2.4 mM in a single
well of a 96-well plate. (a) The locomotion of monocytic cells
without the addition of antibody (ICAM-1) or in the presence of
anti-aL (ICAM-1 1 anti-aL) or anti-MHC class II (ICAM-1 1
anti-MHC) antibodies, was assessed by time-lapse video micros-
copy. (b) A small concentration of PECAM-1 (ICAM-1, PE-
CAM) or vitronectin (ICAM-1, vn), ligands for avb3 integrin,
coated together with ICAM-1 significantly increased the speed of
locomotion of monocytes compared with migration on ICAM-1
alone (ICAM-1). In contrast, coating ICAM-1 with laminin
(ICAM-1, ln) did not affect monocyte locomotion. (c) Migration
on a mixture of ICAM-1 and PECAM-1 could be decreased by
anti-IAP (ICAM-1, PECAM 1 anti-IAP). However, migration
on ICAM-1 alone was not affected by anti-IAP antibodies
(ICAM-1  1 anti-IAP). The experiments were performed as de-
scribed in Materials and Methods. The data represent the mean
speed of locomotion (6 SE), determined independently of ten
different migrating cells for each condition. A representative ex-
periment of three is shown in each case.Weerasinghe et al. avb3 Integrin and Monocyte Migration 603
using L cells instead of e.end2 cells. Neither e.end2 cells
nor L cells form tight junctions, but grow to confluence on
laminin-coated filters in 48 h. L cells express fibronectin,
an avb3 integrin ligand. However, transmigration of avb3
integrin-positive monocytic cells was low through untrans-
fected L cells or L cells expressing PECAM-1. This dem-
onstrated that simply the presence of avb3 ligands could
not ensure efficient transmigration. Surprisingly, however,
b31 monocytic cells were able to transmigrate effectively
through ICAM-1–expressing L cells which also expressed
fibronectin. ICAM-1 is not a known ligand for avb3 but
can bind fibrinogen which in turn can interact with aMb2
on leukocytes (15, 39). This aMb2-fibrinogen–ICAM-1 as-
sociation is able to mediate leukocyte TEM (38). How-
ever, since our L cells did not express fibrinogen, we ruled
out this mechanism. We speculated instead that perhaps
the binding of avb3 to fibronectin was enhancing b2 inte-
grin-mediated migration of the monocytes on ICAM-1.
We used time-lapse video microscopy studies to test this
hypothesis. Both murine and human monocytic cells engage
in  aLb2-dependent migration on recombinant ICAM-1.
Cocoating a ligand for avb3 or cross-linking the av inte-
grin to mimic avb3 integrin occupancy increased the speed
of monocyte locomotion on ICAM-1. The av chain can as-
sociate with other b chains such as b1, b5, and b8 (16, 31,
68). However, cross-linking the av integrin chain on b3 inte-
grin-deficient WEHI-3 monocytic cells failed to enhance
their locomotion on ICAM-1, indicating that b3 is the es-
sential partner chain for av in av-mediated monocyte motil-
ity on ICAM-1. The avb3 integrin is functionally associated
with IAP (7), since IAP has been shown to be necessary for
some b3 integrin-dependent functions (43). The effect of
Figure 9. Migration of WEHI-3 b31 monocytic cells on recombinant ICAM-1 is affected by cross-linking the av integrin chain. (a)
Cross-linking antibodies against av (ICAM-1 1 anti-av) increased the speed of cell locomotion on ICAM-1 from values in the absence
of av cross-linking (ICAM-1), whereas cross-linking MHC class II (ICAM-1 1 anti-MHC) on the cells had no effect. (b) Monocyte mi-
gration on saturating concentrations of VCAM-1 was not enhanced by cross-linking av (VCAM-1 1 anti-av) or a6 (VCAM-1 1 anti-a6)
integrins. (c) Comparison of locomotion of b31 clone 1D10 (solid bars) and b32 clone 3E9 (dotted bars) monocytic cells on recombinant
ICAM-1 before (ICAM-1) and after (ICAM-1 1 anti-av) cross-linking of the av integrin chain. Locomotion of clone 3E9 cells was not
affected by av integrin cross-linking. The experimental procedure is described in Materials and Methods. The data represent the mean
speed of locomotion (6 SE) determined independently, of ten different migrating cells for each condition. A representative experiment
of three is shown.
Figure 10. Human THP-1 cell migration
on ICAM-1 can be regulated by cross-
linking av. Recombinant ICAM-1 was
coated at a saturating concentration of 2.4
mM as before. (a) Cross-linking antibodies
against av (ICAM-1 1 anti-av) increased
cell locomotion from control values for
ICAM-1 alone (ICAM-1), whereas cross-
linking antibodies against a6 (ICAM-1 1
anti-a6) or b2 (ICAM-1 1 anti-b2) inte-
grins had no effect. (b) The enhanced mi-
gration on ICAM-1 after cross-linking the
av integrin (ICAM-1 1 anti-av) could be
decreased by antibodies against the aL in-
tegrin chain (ICAM-1 1 anti-av, 1 anti-
aL). (c) Locomotion of THP-1 on a mix-
ture of ICAM-1/vitronectin (ICAM-1, vn)
was decreased by an antibody against IAP
(ICAM-1, vn 1 anti-IAP), whereas loco-
motion on ICAM-1 alone (ICAM-1) was
not affected by this antibody (ICAM-1 1
anti-IAP). (d) THP-1 cell migration on laminin (ln) was not enhanced by cross-linking av (ln 1 anti-av) or cross-linking a6 (ln 1 anti-a6)
integrins. These experiments were performed as described in Materials and Methods. The data represent the mean speed of locomotion
(6 SE), determined independently of ten different migrating cells for each condition. A representative experiment of three is shown.The Journal of Cell Biology, Volume 142, 1998 604
anti-IAP antibodies on the migration of monocytes on the
mix of ICAM-1 and PECAM-1 or ICAM-1 and vitronec-
tin suggests that IAP is also involved in avb3 integrin-
mediated locomotion on ICAM-1. However, as anti-IAP
antibodies were able to block the TEM of monocytes to a
greater degree than anti-av antibodies alone, it is likely
that IAP may also have an avb3-independent function in
leukocyte TEM.
We previously showed that cross-linking the av integrin
chain on T lymphocytes regulates a4b1 function and cell
migration on VCAM-1 (32). However, in the present study
cross-linking av on monocytes migrating on VCAM-1 did
not affect their speed of locomotion, indicating that the
activity of a4b1 on monocytes is not influenced by occu-
pancy of the avb3 integrin. We also examined whether av
integrins could influence a6 integrins to rule out a nonspe-
cific cross talk mechanism between av integrins and other
integrins on the cell. Cross-linking av on THP-1 cells
migrating on laminin had no effect on their speed of loco-
motion. Finally, to prove that the increase in monocyte
locomotion on ICAM-1 is not an artifact of integrin cross-
linking, we cross-linked MHC class II on murine mono-
cytic cells and chains from two other integrins on THP-1
cells. Cross-linking of MHC, a6, or b2 failed to have any
effect on the migration of monocytic cells on ICAM-1.
Thus, cross-linking specifically the av integrin chain on
monocytic cells enhanced their migration on ICAM-1, and
although the avb3 integrin modulated b2 integrin func-
tion, it did not modulate the function of either a4b1 or a6
integrins on these cells.
The b2 integrins aMb2 and aLb2 are both expressed on
the monocytic cells used in our assays. Does avb3 modu-
late one or both of these integrins? The focus of our
present study was the aLb2 integrin. ICAM-1 has five tan-
demly repeated Ig-like domains (21, 27), and whereas the
binding site for aLb2 is on the first two Ig-like domains
(67), the binding site for aMb2 is on the third Ig-like do-
main (18). The recombinant murine ICAM-1 used in our
experiments consists of just the first two Ig-like domains
which lack the aMb2 binding site but supports murine
monocyte migration, which could be decreased by anti-aL
antibodies. Furthermore, anti-aL antibodies also decreased
the enhanced migration of human THP-1 cells on ICAM-1
brought about by cross-linking the av integrin chain.
Therefore, we concluded that aLb2 is a candidate b2 inte-
grin that responds to occupancy of avb3. This does not
rule out that avb3 integrin occupancy may also affect the
activity of aMb2 in vivo.
The integrin aLb2 forms tight interactions with endo-
thelial ICAM-1. Cell adhesion is regulated both by the af-
finity of the extracellular regions of integrins for their
ligands and by intracellular integrin–cytoskeletal associa-
tions (29). The strength of adhesion between cell surface
receptors and the substrate is therefore a key factor in the
migration process (30). Previous studies have indicated an
inverse correlation between adhesion and cell migration
(19). Studies on the aIIbb3 integrin revealed that high-
affinity states of the receptor results in a decrease in the
Figure 11. Inhibition of the binding of ICAM-1–coated beads to
THP-1 cells immobilized on vitronectin or anti-avb3 antibody.
(a) Cells were immobilized on plastic coated with anti-MHC class
I, ICAM-1, anti-a6, anti-b2, vitronectin, anti-avb3, or anti-avb5
and incubated with ICAM-1–coated beads. Cells immobilized on
anti-avb3 or vitronectin bound less ICAM-1–coated beads. (b)
Cells adhered to the above substrates were incubated with fi-
bronectin- (dotted bars) or BSA-coated beads (solid bars). THP-1
cells immobilized on different substrates displayed no differential
ability to bind either fibronectin- or BSA-coated beads. The bead
binding assays were performed as described in Materials and
Methods. Data are expressed as a binding index, that is the num-
ber of beads bound to 100 cells. Data represent the mean of ten
high power fields 6 SE. A representative experiment of three is
shown.
Figure 12.  Photomicrographs showing the attachment of ICAM-1–
or fibronectin-coated beads to THP-1 cells immobilized on
ICAM-1. THP-1 cells that had adhered to ICAM-1 were treated
with (a) anti-a6 or (b) anti-aL integrin antibodies at 50 mg/ml be-
fore incubation with ICAM-1–coated beads. Less ICAM-1–
coated beads bound to THP-1 cells in the presence of anti-aL.
Cells adherent to ICAM-1 were treated with anti-a6 (c) or anti-
b1 (d) integrin antibodies at 50 mg/ml before incubation with fi-
bronectin-coated beads. Fibronectin-coated bead binding was re-
duced in the presence of anti-b1 antibodies.Weerasinghe et al. avb3 Integrin and Monocyte Migration 605
migration rate of the cell (29), or locking b1 integrins in a
state of high avidity by using activating b1 mAb inhibits
leukocyte extravasation (35). Thus, tight adhesion of re-
ceptors to their substrates is detrimental for cell locomo-
tion. Therefore, it seemed likely that if avb3 occupancy
could modulate monocyte locomotion on ICAM-1, this oc-
cupancy must lead to a deadhesion between aLb2 and
ICAM-1. Monocytes adherent on anti-avb3 or vitronectin
were less efficient in binding ICAM-1–coated beads than
monocytes adherent on ICAM-1, anti-avb5 or other con-
trol substrates. Furthermore, monocytes adherent to anti-
avb3 or vitronectin do not display differential ability to
bind fibronectin-coated beads. This demonstrated that oc-
cupancy of avb3 integrin on the monocyte can decrease
the cell’s binding capacity to ICAM-1. ICAM-1–coated
bead binding to THP-1 cells could be blocked with anti-
bodies against aL. But occupancy of avb3 did not reduce
ICAM-1–coated bead binding to the same extent as the
anti-aL antibodies. However, if avb3 occupancy reduced
the interactions between aLb2 and ICAM-1 totally, the
cell would not be able to migrate on the surface of the en-
dothelium, but would detach instead from the vessel wall.
Modulation of integrin function is therefore a key concept
for cell locomotion. A cell can continuously move forward
only if there is a dynamic regulation of integrin mediated
adhesion and deadhesion. Chemokines can differentially
regulate the avidity of a4b1 integrins by rapidly activating
and deactivating them on monocytes and eosinophils (73,
74). No doubt this mechanism contributes to monocyte
motility on VCAM-1. We previously showed that the avb3
integrin can modulate the activity of a4b1 on T lympho-
cytes and enhance their migration on VCAM-1 (32). Now
we demonstrate that avb3 can modulate the function of
aLb2 integrins on monocytes and favor their migration on
ICAM-1.
How do integrins communicate with each other? Inte-
grins lack intrinsic enzymatic activity to trigger signaling,
but several groups have shown that integrin cytoplasmic
tails can bind to structural cytoskeletal proteins which in
turn interact with components of the intracellular signal-
ing machinery en route to other cell surface receptors (36,
62). Integrins can also interact directly to form cis-acting
complexes on the cell surface. The b2 integrins serve as
signaling partners for leukocyte receptors in this way. The
urokinase plasminogen activator receptor (CD87) and
aMb2 form a functional unit on monocytic cells (64). In-
terestingly, it has recently been shown that the urokinase
plasminogen activator receptor (uPAR) is necessary for
aLb2-mediated leukocyte migration under inflammatory
conditions, and monocyte recruitment to sites of inflam-
mation is impaired in the absence of uPAR (46). The
urokinase receptor can also associate with b1 and b3 inte-
grins on tumor cells adherent on vitronectin which may
regulate tumor cell migration (75). Further work will ad-
dress the mechanism by which the avb3 integrin regulates
aLb2 function on the same cell in monocyte transmigra-
tion.
Peripheral blood monocytes express avb3 albeit at
lower levels than b2 integrins. This level is probably suffi-
cient to mediate the signal required to initiate cell motility
on ICAM-1. However, cell motility on the ECM requires
high expression levels of the integrin (5, 76). The cytokine
granulocyte macrophage colony-stimulating factor (GM-
CSF) can upregulate the expression levels of avb3 on
monocytes (13), and is produced by inflammatory endo-
thelium (50). Interestingly, it has been shown that mice
transgenic for the GM-CSF gene develop accumulations
of macrophages in tissues (37). Therefore, it is likely that
levels of avb3 on monocytes immobilized to inflammatory
endothelium in vivo is upregulated by the influence of
GM-CSF released by the endothelium, which in turn
would promote monocyte locomotion on the endothelium
and the underlying ECM.
Previous studies have emphasized the requirement for
an integrin hierarchy to facilitate the coordinated migra-
tion of leukocytes across the endothelium into tissues. The
a4b1 integrin is involved in the arrest and initial adhesion
of rolling leukocytes to inflammatory endothelium via
VCAM-1. Subsequently, aLb2 mediates tight adhesion of
the leukocyte to vascular ICAM-1 after cellular activation
(10). The aLb2 integrin is then able to downregulate a4b1
and cell adhesion to VCAM-1 (52). In the next step of the
integrin hierarchy, the avb3 integrin downregulates aLb2
activity, modulating leukocyte adhesion to ICAM-1, and
enabling the cell to migrate effectively across the endothe-
lium.
In summary, we show that the avb3 integrin is involved
in the transition between tight adhesion of monocytes to
the vascular endothelium and subsequent diapedesis. This
may be an important mechanism not only for the TEM of
monocytes but also for other leukocyte subsets that use b2
integrins during transendothelial diapedesis.
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